Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Sanja B TurturroMatthew S NajorTimothy YungLiam PorttChristopher S MalarkeyAbde M AbukhdeirMelody A CobleighPublished in: Breast cancer research and treatment (2019)
Our findings suggest that breast cancers with loss of p85α may not respond to mTOR inhibition, but may be sensitive to MEK inhibition.